Drug prices are incomprehensible and the cost of oncology treatments keeps rising, writes Dr. Peter Bach of the Center for Health Policy and Outcomes at Memorial Sloan-Kettering Cancer Center. Incentives should be in place for drugmakers to bring me-too treatments to market in order to undercut the prices of competing therapies, and insurers' policies should help those companies gain market share, Bach writes.

Full Story:

Related Summaries